The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?

Table 3 Ongoing trials of IL-18 blocking therapies

NCT ID	Indication	Drug	Design	Inclusion/Exclusion	Primary Endpoints
NCT02398435	AOSD	IL-18BP	OL –> DE	Yamaguchi [40]	AEs, change from baseline
NCT03113760	NLRC4-GOF & XIAP	IL-18BP	OL –> RW	gene, CRP or Ferritin, mAIDAI	Time to flare
NCT04641442	NLRC4-GOF	Anti-IL-1β/IL-18 bi- specific	OL –> RW	gene, IL-18, CRP or Ferritin, PGA	Time to flare
NCT04752371	AOSD	Anti-IL-18 monoclonal	OL –> DE	Yamaguchi [40]	AEs, change from baseline

AOSD Adult-onset Still disease, GOF Gain-of-function, OL Open-label, DE Dose escalation, RW Randomized withdrawal, mAIDAI Modied autoinflammatory disease activity index [41], PGA Physician’s global assessment, AEs Adverse events

ISSN: 1546-0096